TNF Pharmaceuticals is researching groundbreaking treatments to address serious and debilitating autoimmune and inflammatory illnesses.
TNF Pharmaceuticals has raised $7.0M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in September 2025.
TNF Pharmaceuticals's investors include PharmaCyte Biotech.
TNF Pharmaceuticals is headquartered in Baltimore, United States.
TNF Pharmaceuticals is researching groundbreaking treatments to address serious and debilitating autoimmune and inflammatory illnesses.
TNF Pharmaceuticals is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"TNF Pharmaceuticals — Funding & Investors." VCBacked, September 2, 2025, https://www.vcbacked.co/company/tnf-pharmaceuticals. Accessed October 8, 2026.
VCBacked. (2025). TNF Pharmaceuticals — Funding & Investors. Retrieved October 8, 2026, from https://www.vcbacked.co/company/tnf-pharmaceuticals
{{cite web |title=TNF Pharmaceuticals — Funding & Investors |url=https://www.vcbacked.co/company/tnf-pharmaceuticals |website=VCBacked |access-date=October 8, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated